
Taking a fertility or reproductive health offering into a new country isn't simply a translation exercise. Winston Francois develops the market entry and growth plan around the regulatory, clinical, and employer-benefit realities of every market you enter.
Reproductive health laws differ by country in ways that directly influence what you can offer and communicate
What's a standard covered service in one country may be restricted, require additional consent processes, or carry different age and eligibility rules in another. A growth plan that copies the domestic service design and messaging into a new market without a country-specific legal review risks offering something that isn't actually compliant, or messaging a service in a way that draws regulatory attention it wouldn't get at home.
Clinical networks don't carry over, and quality signals must be established again from scratch in every market
A domestic reputation built on partnerships with well-known clinics means nothing to an employer or member in a new country evaluating an unfamiliar brand with no local clinical footprint yet. Expansion plans that lead with brand messaging before the clinical network is actually built in-market put the growth motion ahead of the thing that makes the offer credible.
Employer benefit expectations and norms vary based on each country's underlying healthcare system
In markets with strong public healthcare systems, a fertility benefit competes against a very different baseline expectation than in a market where employer-sponsored benefits carry most of the weight, which changes both the pitch to HR buyers and the price point that reads as reasonable. A single global pitch deck applied everywhere undersells the offer in some markets and oversells it in others.
Multinational employer contracts can create a gap between global deal terms and the realities of local delivery
Landing a multinational employer's global HQ often means promising consistent benefit delivery across every country the employee population sits in, but the local clinical network, legal framework, and even the core service design may not be ready in every one of those markets at signing. Sales teams that promise global parity before growth has confirmed local readiness create a delivery gap that shows up during rollout, not during the pitch.
We begin every market entry with a country-specific legal and regulatory review of the service design itself, not only the marketing copy, confirming that the offer is compliant before any go-to-market work starts in that market.
In each new market, we put clinical network development ahead of spending on brand and demand generation, viewing local clinical credibility as the foundation for the growth motion rather than something developed alongside customer acquisition.
We create market-specific pricing and positioning that account for each country's baseline healthcare expectations instead of translating one global pitch deck, helping the value proposition resonate with HR buyers based on their local comparisons.
For multinational employer agreements, we help match sales commitments to actual local delivery readiness in each market, identifying where a global contract requires a phased rollout rather than promising a same-day launch across every country in the account.
The greatest international expansion risk in this category isn't growing slowly; it's growing quickly in a market before the clinical network or legal review has caught up.
We manage international growth as a 90-day sprint for each target market. Days 1-30 cover the legal and regulatory review and evaluation of the local clinical landscape to establish what's realistically possible in that country. Days 30-60 develop the market-specific positioning, pricing, and clinical partnership plan. Days 60-90 begin initial go-to-market activity after the clinical network has sufficient coverage to handle real demand.
What sets this apart from a typical international expansion engagement is our refusal to put brand and demand activity ahead of clinical network readiness, even if a global employer deal is pressing for a quicker rollout. We would rather delay one market's launch than commit to a delivery experience that isn't ready.
We also approach market prioritization as a growth decision in its own right, ranking target countries by regulatory complexity and the feasibility of clinical partnerships instead of market size alone, because the largest market isn't always the easiest to enter.
The first 30 days focus on legal review and an assessment of the target market's clinical landscape, completed in partnership with local counsel engaged by your team. Days 30-60 develop the market entry plan, including pricing, positioning, and clinical partnership outreach. Days 60-90 support initial launch efforts after clinical coverage is confirmed.
Your team must engage local legal counsel to conduct the regulatory review, as we coordinate with counsel rather than replace it, and give us access to your existing clinical partnership team so we can assess what network development is feasible. Throughout the process, we work directly with your international growth lead to keep the plan aligned with real operational capacity.
Most entries into a single market take 3-5 months from the initial review through launch readiness, while additional markets can proceed in parallel or sequentially based on team capacity.
If your fertility & reproductive health company needs international growth leadership, we should talk.

Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Most single-market entry engagements cost $30,000 to $60,000, based on regulatory complexity and the extent of clinical network development required. Markets with clear regulatory environments and established clinical relationships cost less than those needing extensive legal review and network development from scratch.
Allow at least 4-6 months from the initial legal review to achieving a launch-ready market, and longer when the clinical network requires substantial development. Compressing this timeline to hit a sales deadline is the most common reason delivery gaps emerge after a multinational contract is signed.
We work directly with the local legal counsel engaged by your team on regulatory review and collaborate with your clinical partnerships team to evaluate network feasibility. We replace neither function; instead, we shape the growth plan around what they determine is genuinely achievable in each market.
Most international expansion models are designed for software products, where entering a market is largely a localization and marketing effort. We place clinical network development and legal review before demand generation because, in this category, the offering must be verified as compliant and deliverable before growth activity begins.
We measure time-to-launch-readiness against the initial plan, the employer pipeline created after local go-to-market activity starts, and delivery consistency for multinational accounts compared with commitments made at signing. The final measure matters most because a quick launch that cannot deliver harms the global relationship, not only the local one.
Growth-stage companies that have at least one proven domestic market and either a genuine multinational employer opportunity or a strategic reason to expand are the strongest fit. Earlier-stage companies that are still validating their domestic model are generally better served by concentrating growth strategy efforts at home first.
Tuesday, June 16, 2026
Frank Growth – Episode 224 – The Bootstrapper’s Revenge with Alex Roy
Tuesday, October 20, 2026
Frank Growth – Episode 242 – Why AI Slop Backfires with Nicole Cassese
Tuesday, October 13, 2026
Frank Growth – Episode 241 – What AI Still Can’t Do with Will Sartorius
Tuesday, November 17, 2026
Frank Growth – Episode 246 – Google Analytics for Real Stores with Angie Westbrock
Ready to unlock your growth?
Book Free Call